Allman to lead Merck's hepatitis C effort

Share this article:
Merck is launching a chronic hepatitis C awareness campaign featuring rocker and hepatitis C sufferer Gregg Allman, whose Allman Brothers Band headlined a benefit concert on World Hepatitis Day on July 27, in New York.
Allman underwent a liver transplant a year ago because of chronic hepatitis C and said in a statement: “I want to tell [sufferers], don't wait. Doing nothing is not an option. They need to talk with their doctor.”
Three million Americans have the disease, which can damage the liver over time and lead to cirrhosis, end-stage liver disease and liver cancer. As many as four-fifths of those infected don't know they have the virus, said Merck.
“When a person like Gregg Allman comes forward to speak about his personal experience, it is extremely powerful, and we are grateful to him for his commitment to helping motivate other people with chronic hepatitis C to take action,” said Mark Timney, president, global human health, US market, Merck.
The campaign, dubbed Tune In to Hep C, is being co-sponsored by the American Liver Foundation, whose acting CEO Newton Guerin said: “Gregg's willingness to share his story will open the door for meaningful dialogue that can help reduce stigma and the lack of understanding surrounding chronic hepatitis C.
Merck's Victrelis, the first in a new class of hepatitis C drugs, won FDA approval in May, followed weeks later by rival Incivek, from Vertex Pharmaceuticals.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...